Morgan Stanley has ranked its European diagnostics coverage by exposure to China’s National Healthcare Security Administration’s lab-fee reform, published on August 14, which targets over 600 test reagents and analytes.
Analysts project a base-case net price compression of 15% for affected products, below the previously cited 20%-40% multiplex discount range, after accounting for volume offsets and premium add-ons. The assessment evaluates earnings before interest and taxes (EBIT) exposure by FY27, assuming a full 100% pricing drop-through.
bioMérieux leads the ranking with the highest exposure, estimated at approximately 5% of FY27 EBIT. China contributes about 5% of group sales, split roughly 80% in microbiology and 20% in immunoassay. Microbiology exposure includes culture, microbial identification, and antimicrobial susceptibility testing, primarily through the BACT/ALERT and VITEK platforms, while immunoassay risks stem from the China PCT franchise.
DiaSorin follows with roughly 2% EBIT exposure. China accounts for about 3% of group sales, entirely within immunodiagnostics, covering infectious disease, bone and mineral, endocrinology, and specialty immunology testing. The company previously guided to a €5 million impact from China’s volume-based procurement in 2026 and shuttered its Shanghai manufacturing site in Q4 FY25.
Siemens Healthineers ranks third with about 1% group EBIT impact. China represents the highest share of diagnostics sales among the four companies at roughly 7%, spanning core lab, specialty lab, and point-of-care testing, including glucose, blood gas, TSH, and coagulation items. Analysts note potential understatement of segment sensitivity due to low diagnostics margins at 3% (excluding a tariff refund in FQ3'26), visible China VBP weakness, and an upcoming diagnostics carve-out within 12-24 months.
Qiagen ranks lowest in exposure, also at about 1%. China contributes around 4% of group sales, evenly split between life sciences and diagnostics (excluding QIAStat-Dx and QuantiFERON). Exposure centers on molecular tests, including HPV, pathogen nucleic-acid amplification, pharmacogenomics, and NGS. Analysts highlight potential pricing cushions from premium molecular add-ons such as quantitative, RNA, high-sensitivity, and whole-genome/exome sequencing tests.
